On August 18th, Green Bamboo Biology-B (02480) announced that a head-to-head comparative study of its core product LZ901 and the recombinant glycoprotein E(gE) subunit vaccine HZ/su vaccine (Shingrix®) was conducted, and positive immunogenicity and safety data were obtained. This study recruited 301 healthy adults aged 50 and above. The results showed that LZ901 was superior to the HZ/su vaccine in both cellular immunogenicity and safety.

In terms of specific immunogenicity results, LZ901 did not perform worse than the HZ/su vaccine in CD4+ and CD8+T cell immune responses. The proportion of gE specific CD4+T cell responders was 83.0%, while that of the HZ/su vaccine was 58.1%. The proportion of gE specific CD8+T cell responders was 46.8%, and that of HZ/su vaccine was 8.8%.

In terms of safety, the adverse reaction rate of LZ901 was 41.1%, significantly lower than 87.9% of the HZ/su vaccine, and most of the reported reactions were mild or moderate. Among the LZ901 subjects, only one reported a grade 3 adverse reaction, while among the HZ/su vaccine subjects, there were nine.

Further detailed information of the research results has been published in the journal Nature Communications

https://finance.eastmoney.com/a/202508183486570250.html